26 June, 2024 in Investor Relations Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal
20 June, 2024 in Investor Relations Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
13 June, 2024 in Investor Relations Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
04 June, 2024 in Investor Relations Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
03 June, 2024 in Investor Relations FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
22 May, 2024 in Investor Relations Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
09 May, 2024 in Investor Relations Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
25 April, 2024 in Investor Relations Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
18 April, 2024 in Investor Relations, Videos Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device
09 April, 2024 in Investor Relations Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
